Microsoft announced its Cloud deal with PAREXEL International, a biopharmaceutical services organization driving innovation across the life sciences industry.
PAREXEL will use Microsoft’s cloud infrastructure, intelligent services, and research and development capabilities. PAREXEL will be moving Informatics technology and services onto Microsoft Azure.
Microsoft and PAREXEL will also jointly develop innovative, patient-centric technologies and cloud-based services to support clinical research and market access for life science clients.
“Drug development is becoming more complex, while innovations including social media, analytics, mobile technology and the Internet of Things are enabling a more patient-centric approach,” said Xavier Flinois, president, PAREXEL Informatics.
“By combining the intelligent capabilities of Microsoft Azure with PAREXEL’s biopharmaceutical expertise, we will help life science companies to accelerate the drug-development and commercialization process with the Microsoft Cloud,” said Peggy Johnson, executive vice president, Business Development at Microsoft.
Businesses looking to digitally transform with Microsoft Azure benefit from Microsoft’s more than $1 billion investment in security research per year and 42 datacenter regions.
